We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+17.46%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.94B
AUM Growth
+$209M
Cap. Flow
+$157M
Cap. Flow %
8.08%
Top 10 Hldgs %
37.79%
Holding
268
New
72
Increased
34
Reduced
55
Closed
76

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.3M
2
SONX
Sonendo, Inc.
SONX
+$7.34M
3
NTRA icon
Natera
NTRA
+$6.8M
4
AZTA icon
Azenta
AZTA
+$6.45M
5
QTRX icon
Quanterix
QTRX
+$5.89M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$22.4M
2
ILMN icon
Illumina
ILMN
+$11.7M
3
AZN icon
AstraZeneca
AZN
+$9.6M
4
OM icon
Outset Medical
OM
+$8.46M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.3M

Sector Composition

Rank Sector Weight
1 Healthcare 27.35%
2 Industrials 0.25%
3 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRTA icon
101
Prothena Corp
PRTA
$475M
$3.86M 0.2%
+64,000
New +$3.75M
NVCR icon
102
NovoCure
NVCR
$2.05B
$3.67M 0.19%
+50,000
New +$3.76M
TRUP icon
103
PUT
Trupanion
TRUP
$1.33B
$3.56M 0.18%
75,000
– –
RGEN icon
104
PUT
Repligen
RGEN
$9.35B
$3.35M 0.17%
19,800
-10,200
-34% -$1.85M
EVH icon
105
Evolent Health
EVH
$471M
$3.26M 0.17%
+116,200
New +$3.33M
TGTX icon
106
CALL
TG Therapeutics
TGTX
$7.58B
$2.96M 0.15%
+250,000
New +$1.81M
PCVX icon
107
Vaxcyte
PCVX
$8.88B
$2.95M 0.15%
+61,528
New +$2.41M
RCKT icon
108
PUT
Rocket Pharmaceuticals
RCKT
$374M
$2.94M 0.15%
+150,000
New +$2.76M
STE icon
109
Steris
STE
$23.1B
$2.86M 0.15%
+15,500
New +$2.73M
AVXL icon
110
CALL
Anavex Life Sciences
AVXL
$316M
$2.78M 0.14%
300,000
+100,000
+50% +$1.07M
ISRG icon
111
Intuitive Surgical
ISRG
$142B
$2.65M 0.14%
10,000
-9,732
-49% -$2.37M
ALGN icon
112
CALL
Align Technology
ALGN
$12.4B
$2.64M 0.14%
+12,500
New +$2.5M
NVCR icon
113
CALL
NovoCure
NVCR
$2.05B
$2.57M 0.13%
+35,000
New +$2.63M
INCY icon
114
Incyte
INCY
$24.5B
$2.44M 0.13%
+30,400
New +$2.33M
TWST icon
115
PUT
Twist Bioscience
TWST
$7.85B
$2.38M 0.12%
+100,000
New +$2.9M
KDNY
116
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$2.36M 0.12%
+90,000
New +$1.99M
TSVT
117
DELISTED
2seventy bio
TSVT
$2.35M 0.12%
251,309
-73,691
-23% -$1.04M
RXDX
118
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$2.31M 0.12%
21,000
-8,188
-28% -$531K
INBX
119
DELISTED
Inhibrx, Inc. Common Stock
INBX
$2.31M 0.12%
+93,575
New +$2.75M
ORMP icon
120
CALL
Oramed Pharmaceuticals
ORMP
$178M
$2.23M 0.12%
185,500
– –
NUVL
121
DELISTED
Nuvalent
NUVL
$2.1M 0.11%
+70,523
New +$1.97M
ICAD
122
DELISTED
iCAD Inc
ICAD
$2.03M 0.1%
1,108,669
+228,111
+26% +$425K
APYX icon
123
CALL
Apyx Medical
APYX
$126M
$1.97M 0.1%
+840,000
New +$2.56M
ESPR
124
DELISTED
Esperion Therapeutics
ESPR
$1.92M 0.1%
308,313
-23,810
-7% -$170K
NARI
125
PUT
DELISTED
Inari Medical, Inc. Common Stock
NARI
$1.91M 0.1%
30,000
-14,000
-32% -$1.02M
3 4
5
6 7

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2022 Portfolio in Review

As of Q4 2022, Pura Vida Investments held 268 positions worth $1.94B, up 12% from $1.73B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Pura Vida Investments deployed $157M of net new capital in Q4 2022, opening 72 new positions and adding to 34 existing holdings. Its largest new stake was Natera: 165,000 shares worth $6.63M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 35% a quarter earlier, followed by Industrials and Materials.

On the sell side, the largest reduction was United Therapeutics, an estimated $22.4M trimmed.

  • Pura Vida Investments's largest Q4 2022 buy was Natera: 165,000 shares worth $6.63M.
  • Pura Vida Investments added most to Biogen in Q4 2022, an estimated $16.3M increase.
  • Pura Vida Investments's biggest Q4 2022 reduction was United Therapeutics, cutting an estimated $22.4M.
  • Pura Vida Investments fully exited Illumina in Q4 2022, selling an estimated $11.7M.
  • Pura Vida Investments's ten largest holdings make up 38% of its $1.94B portfolio in Q4 2022.
  • Pura Vida Investments opened 72 new positions and closed 76 in Q4 2022.
  • Pura Vida Investments's portfolio value rose 12% quarter-over-quarter to $1.94B.

Based on Pura Vida Investments's 13F filing for Q4 2022, filed 14 Feb 2023.